诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

未开盘 12-11 16:00:00 EST

50.29

+1.24

+2.53%

盘后50.10

-0.19-0.38%

19:59 EST

最高50.54	最低49.59	成交量1,560万
今开49.96	昨收49.05	日振幅1.95%
总市值2,232亿	流通市值1,603亿	总股本44.39亿
成交额7.82亿	换手率0.49%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":50.29,"timestamp":1765486800000,"preClose":49.05,"halted":0,"volume":15601182,"hourTrading":{"tag":"盘后","latestPrice":50.1,"preClose":50.29,"latestTime":"19:59 EST","volume":208045,"amount":10470372.5942,"timestamp":1765501180238},"delay":0,"floatShares":3187922885,"shares":4439052849,"eps":3.665526,"marketStatus":"未开盘","change":1.24,"latestTime":"12-11 16:00:00 EST","open":49.96,"high":50.54,"low":49.585,"amount":782417998.7184,"amplitude":0.01947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.665526,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":0,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":49.05,"dividendRate":0.033562,"preHourTrading":{"tag":"盘前","latestPrice":49.97,"preClose":49.05,"latestTime":"09:29 EST","volume":859749,"amount":42885053.894099995,"timestamp":1765463399999},"postHourTrading":{"tag":"盘后","latestPrice":50.1,"preClose":50.29,"latestTime":"19:59 EST","volume":208045,"amount":10470372.5942,"timestamp":1765501180238},"volumeRatio":1.028184,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1768539600000,"strike":"60.0","timestamp":1765483056392,"price":0.38,"volume":5000,"amount":190000,"type":"-"},{"symbol":"NVO","call":true,"expireDate":1766120400000,"strike":"50.0","timestamp":1765465722491,"price":1.41,"volume":4919,"amount":693579,"type":"+"}]},"impliedVol":0.4388,"impliedVolPercentile":0.184},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2590557847","title":"诺和诺德在印度推出糖尿病治疗药物Ozempic。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557847","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590557847?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:45","pubTimestamp":1765521953,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4588","IE00BKVL7J92.USD","BK4532","NVO","BK4599","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007"],"gpt_icon":0},{"id":"2590515212","title":"诺和诺德(NVO)盘前升1.75% 分析师谨慎看待其价值回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515212","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515212?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:59","pubTimestamp":1765457968,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前股价延续升势，暂升1.75%，报49.91美元。诺和诺德今年股价暴跌，甚至退回到了2021年减肥药热潮爆发前的水平。尽管如此，分析师仍谨慎看好该公司股价恢复到合理水平。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"295294","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1093756168.USD","BK4532","BK4585","LU0154236417.USD","BK4599","LU1093756325.SGD","BK4007","NVO","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1150141925","title":"诺和诺德股价短暂转负，因礼来称下一代药物在减重方面超越Zepbound，最终上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150141925","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150141925?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:00","pubTimestamp":1765454446,"startTime":"0","endTime":"0","summary":"诺和诺德股价短暂转负，因礼来称下一代药物在减重方面超越Zepbound，最终上涨1.8%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1035775433.USD","IE00BKPKM429.USD","LU2063271972.USD","IE00BK4W5L77.USD","LU1868837300.USD","LU2361044865.SGD","BK4534","LU0238689110.USD","LU0006306889.USD","LU1323610961.USD","IE00BFSS8Q28.SGD","LU1551013425.SGD","IE00BKDWB100.SGD","LU0114720955.EUR","LU0786609619.USD","LU1623119135.USD","LU2552382058.USD","LU1720051108.HKD","LU0432979614.USD","LU0456855351.SGD","LU1989771016.USD","LU2108987350.USD","LU2168564495.EUR","IE00BJJMRY28.SGD","LLY","SG9999018865.SGD","LU0234572021.USD","LU2237443895.HKD","NVO","LU1868836591.USD","LU2087625088.SGD","LU0708995401.HKD","BK4581","LU2357305700.SGD","LU0820561909.HKD","LU2237438978.USD","SG9999018857.SGD","LU0689472784.USD","LU2461242641.AUD","LU2237443978.SGD","LU0889565916.HKD","LU0823434583.USD","IE00BFSS7M15.SGD","LU2471134796.USD","LU2552382132.HKD","SG9999014880.SGD","LU1057294990.SGD","LU0203201768.USD","LU2491049909.HKD","LU0354030511.USD","LU0320765059.SGD","LU0058720904.USD","LU0882574055.USD","LU1093756168.USD","LU0122379950.USD","LU0316494557.USD","SGXZ57979304.SGD","LU1548497426.USD","LU0353189763.USD","LU0320765992.SGD","LU2237443382.USD","BK4585","LU0823434740.USD","LU2237443622.USD","IE00BK4W5M84.HKD","LU1720051017.SGD","IE00B4JS1V06.HKD","LU0882574139.USD","LU2361045086.USD","LU0109391861.USD","LU1061106388.HKD","SG9999015945.SGD","LU0198837287.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0385154629.USD","BK4516","BK4599","SGXZ99366536.SGD","LU2236285917.USD","LU0417517546.SGD","LU0256863902.USD","BK4533","LU2264538146.SGD","LU1127390331.HKD","LU2746668461.USD","LU2491050154.USD","IE00BJJMRX11.SGD","SG9999015952.SGD","SG9999014898.SGD","LU0096364046.USD","LU0640476718.USD","BK4007","IE00B7KXQ091.USD","LU1023059063.AUD","IE0002141913.USD","SGXZ51526630.SGD","LU0353189680.USD","IE0004445239.USD","LU2211815571.USD","LU2471134879.HKD","LU0097036916.USD","LU2106854487.HKD","BK4588","SG9999014906.USD","IE0009355771.USD","LU0823416689.USD","LU1868836914.USD","LU2168564222.USD","IE00BJLML261.HKD","LU2468319806.SGD","IE00B1XK9C88.USD","LU0106261372.USD","LU0471298777.SGD","LU1814569148.SGD","LU0094547139.USD","LU2491050071.SGD","SG9999001176.SGD","LU2089984988.USD","LU0289739699.SGD","GB00BDT5M118.USD","LU0672654240.SGD","LU2462157665.USD","LU2361044949.HKD","LU1280957306.USD","SGXZ81514606.USD","LU1232071149.USD","SG9999015978.USD","LU0109394709.USD","IE00BN29S564.USD","LU2750360997.AUD","LU2168563687.JPY","LU2471134952.CNY","LU1064131342.USD","LU0820561818.USD","LU1868836757.USD","LU2023250504.SGD","SG9999017495.SGD","IE00B1BXHZ80.USD","LU2456880835.USD","LU2602419157.SGD","LU1983299246.USD","LU0466842654.USD","LU1868837136.USD","IE0005OL40V9.USD","IE00B775H168.HKD","IE00BWXC8680.SGD","LU0061475181.USD","LU2750360641.GBP","SGXZ31699556.SGD","LU1366192091.USD","LU1804176565.USD","LU2471134523.USD","SG9999015986.USD","LU2324357040.USD","LU2746668974.SGD","LU2360106947.USD","LU1917777945.USD","LU2237443549.SGD","LU1974910355.USD","LU1712237335.SGD","LU0203202063.USD","IE00BJT1NW94.SGD","LU0354030438.USD","LU2168564149.EUR","LU2112291526.USD","LU1551013342.USD","LU0079474960.USD","LU1069344957.HKD","LU1267930730.SGD","LU2168564065.EUR","LU2552382215.SGD","LU0266013472.USD","LU0256863811.USD","IE0004445015.USD","LU1988902786.USD","LU1291159041.SGD","LU2417539215.USD","LU2265009873.SGD","LU2237443465.HKD","SG9999013999.USD","LU0323591593.USD","LU0471298694.HKD","SG9999001176.USD","LU0943347566.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","SG9999014914.USD"],"gpt_icon":0},{"id":"2590651590","title":"诺和诺德股价跌回2021年水平 分析师谨慎看好估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2590651590","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590651590?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:27","pubTimestamp":1765452459,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK4588","LU0154236417.USD","NVO","IE00BKVL7J92.USD","BK4585","BK4532"],"gpt_icon":0},{"id":"1171599262","title":"2025年暴跌50%！诺和诺德遭遇史上最差一年，“减肥药狂潮”仿佛从未发生","url":"https://stock-news.laohu8.com/highlight/detail?id=1171599262","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171599262?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441808,"startTime":"0","endTime":"0","summary":"今年以来，诺和诺德股价暴跌逾50%，且几乎抹去了自2021年Wegovy获批用于减肥治疗以来的惊人涨幅。礼来后来居上，诺和诺德面临巨大挑战诺和诺德面临的最大威胁来自竞争对手礼来公司的强势表现。礼来股价今年飙升超过28%，与诺和诺德的暴跌形成鲜明对比。Zealand Pharma股价今年也下跌近30%，显示整个欧洲减肥药板块都面临压力。诺和诺德显然没有死。2026年诺和诺德CagriSema药物与礼来Zepbound的直接对比试验结果，以及公司明年的初步业绩指引将成为市场关注焦点。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":{"source":"lsy1762389672944","url":"https://wallstreetcn.com/articles/3761178","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3761178","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1762389672944","symbols":["LLY","NVO"],"gpt_icon":1},{"id":"2590561218","title":"2026年畅销药预测TOP10","url":"https://stock-news.laohu8.com/highlight/detail?id=2590561218","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590561218?lang=zh_cn&edition=full","pubTime":"2025-12-11 13:14","pubTimestamp":1765430055,"startTime":"0","endTime":"0","summary":"2026年畅销药预测TOP10注：预测数据仅涵盖由指定全球营销合作伙伴预订的销售额，例如赛诺菲负责的度普利尤单抗以及BMS负责的阿哌沙班。与去年对2025年的预测相比，2026年TOP10的产品名单并未发生变化，显示出头部阵营的稳定性。用于2型糖尿病的Mounjaro预计销售额将达258亿美元，跃升至榜单第二位；而用于肥胖症的Zepbound则预计成为第五大畅销药，并成为TOP10中绝对销售额和同比增长率最高的“增长之王”。其2026年预计销售额为197亿美元，排名降至第六位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121113262695370e0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121113262695370e0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014567.USD","LU1929549753.HKD","SG9999001440.SGD","LU0203347892.USD","IE00BKVL7J92.USD","LU1061106388.HKD","LU1989771016.USD","IE0009355771.USD","BK4588","SG9999014542.SGD","BK4534","LU0203345920.USD","LU1093756168.USD","LU1917777945.USD","LU2125154935.USD","LU2461242641.AUD","LU1699723380.USD","LU2468319806.SGD","BK4007","LU2361044949.HKD","LU2125154778.USD","LU0234572021.USD","SG9999015341.SGD","LU0861579265.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU1941712348.USD","LU0266013472.USD","LU2089984988.USD","LU1941712264.USD","LU1585245621.USD","LU1430594728.SGD","LU1037948897.HKD","LU0265550946.USD","BK4599","SG9999002224.SGD","BK4516","LU1934455277.USD","SG9999001176.USD","BK4550","LU0320765646.SGD","IE0002141913.USD","BK4532","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1989772923.USD","IE00BLSP4452.SGD","NVO","LU0965509283.SGD","LU0985320562.USD","LU1162221912.USD","LU1023059063.AUD","LU2324357040.USD","LU1116320737.USD","LU2361044865.SGD","LU1571399168.USD","IE00BN8TJ469.HKD","IE00BLSP4239.USD","BK4585","LU1035773651.USD","LU2361045086.USD","LU0098860793.USD","LU0965509010.AUD","LU0289739699.SGD","LU1057294990.SGD","LU1934455194.USD","LU1934455863.HKD","IE000M9KFDE8.USD","LU0965509101.SGD","LU0965508806.USD","LU0208291251.USD","LU0265550359.USD","LU0211331839.USD","IE00BSNM7G36.USD","LU1989772840.SGD","LU1116320901.HKD","LU2106854487.HKD","LU0122379950.USD","SGXZ57979304.SGD","IE00BZ1G4Q59.USD","LU1066051225.USD","LU1037948541.HKD","SG9999015358.SGD","LU0320765489.SGD","SG9999013999.USD","BK4559","LU0058720904.USD","IE00B1BXHZ80.USD","SG9999014559.SGD","BK4533","LU1093756325.SGD","IE00BBT3K403.USD","IE00B4R5TH58.HKD","LU1066051498.USD","LU2023250843.SGD","SG9999002232.USD","LU0106261372.USD","LU2112291526.USD","MRK","LU1974910355.USD","LU2360032135.SGD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1291159041.SGD","SG9999001176.SGD","LU0238689110.USD","SG9999014575.USD","LU2023250504.SGD","LU1983299246.USD","LLY","LU1066051811.HKD","LU0154236417.USD","LU1069347547.HKD"],"gpt_icon":1},{"id":"1169452002","title":"减肥药概念走强，GPCR涨超5%，诺和诺德涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169452002","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169452002?lang=zh_cn&edition=full","pubTime":"2025-12-10 23:26","pubTimestamp":1765380382,"startTime":"0","endTime":"0","summary":"罗氏控股涨超3%，礼来跟涨。","market":"us","thumbnail":"https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8c3694a08f44a67f8ee972cef2b11b95","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","GPCR","RHHBY","LLY"],"gpt_icon":0},{"id":"2590344084","title":"诺和诺德完成对生物制药公司Akero的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344084","media":"动脉网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344084?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:00","pubTimestamp":1765288800,"startTime":"0","endTime":"0","summary":"诺和诺德12月9日宣布已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金（总价值达47亿美元）及一项不可转让的或有价值权（CVR）作为交易对价，全面收购了Akero所有已发行的普通股及等价物。随着交易的圆满结束，Akero正式成为诺和诺德旗下的全资子公司，其普通股也将随之从纳斯达克全球精选市场退市，不再进行上市交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","AKRO","LU0154236417.USD","LU1093756168.USD","BK4007","BK4585","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","NVO","BK4532","LU1093756325.SGD"],"gpt_icon":0},{"id":"2590341068","title":"诺和诺德：已完成对Akero的收购，其普通股将不再在纳斯达克全球精选市场上市或交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341068","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590341068?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:56","pubTimestamp":1765288564,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4599","LU1093756168.USD","NVO","BK4588","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","BK4532","AKRO","BK4585"],"gpt_icon":0},{"id":"2590399358","title":"诺和诺德：乐城引进帕西生长激素注射液，为GHD患儿提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2590399358","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590399358?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:06","pubTimestamp":1765249561,"startTime":"0","endTime":"0","summary":"帕西生长激素注射液则采用了一项在国际上已有36年应用历史的成熟技术——脂肪酸衍生化制药技术。这项技术已成功应用于地特胰岛素、司美格鲁肽等多个经典药物中，验证了其可靠性与有效性。此外，帕西生长激素分子与人体生长激素分子近似，延长代谢主要依赖于自身体内白蛋白，从7年临床实验随访与真实世界使用观察，药物安全性特征良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110822a72c5c50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110822a72c5c50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVO","IE00BKVL7J92.USD","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1093756168.USD","BK4588","BK4007","BK4585"],"gpt_icon":1},{"id":"2590395790","title":"年耗数十万！阿尔茨海默病新药入商保，能否破解“记忆困境”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395790","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395790?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:34","pubTimestamp":1765247654,"startTime":"0","endTime":"0","summary":"日前，在2025创新药高质量发展大会上，我国首版《商业健康保险创新药品目录》正式发布。两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选。自今年起，国家医保部门首次探索“商业健康保险”联动医保目录机制，聚焦创新程度高、临床价值大、患者获益显著的药物，旨在通过医保与商业险的协同发力，进一步提高人民群众对重大疾病创新疗法的可负担性和可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209103645a43c9924&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209103645a43c9924&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4132","LU1093756325.SGD","NVO","BK4585","BK4007","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4213","BK4532","BK4588","IE00BKVL7J92.USD","LLY"],"gpt_icon":1},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4230","01228","BK4588","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","02171","BK4532","LU1093756325.SGD","BK4599","LU0154236417.USD","IE00BKVL7J92.USD","BK4007","688235","02196","02161","BK4022","06160","ONC"],"gpt_icon":0},{"id":"2589963378","title":"印度Healthify与诺和诺德达成合作后，计划与更多减肥药企建立合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2589963378","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589963378?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:23","pubTimestamp":1764930180,"startTime":"0","endTime":"0","summary":"印度健康科技初创公司 Healthify 的首席执行官表示，在与诺和诺德印度子公司签署合作协议后，该公司正洽谈与更多减肥药企建立合作，以提供健康、营养及生活方式指导服务。　　此次合作是 Healthify 首次与药企达成此类合作，该公司希望通过类似协议扩大其付费用户群体。　　Healthify 主营健康数据追踪业务，同时提供营养与健身建议。　　瓦希什特指出，这项患者支持计划是 Healthify 更广泛减肥计划的一部分，目前该减肥计划已为公司贡献了两位数的营收占比。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-05/doc-infztyka7677713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU1093756325.SGD","BK4588","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","IE00BKVL7J92.USD","MNDmain","LU1093756168.USD","BK4532","BK4585"],"gpt_icon":1},{"id":"2588988906","title":"司美格鲁肽等GLP-1药物写入WHO全球指南用于肥胖症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988906","media":"21财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588988906?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:01","pubTimestamp":1764849707,"startTime":"0","endTime":"0","summary":"为应对全球日益严峻的肥胖健康挑战，近日，世界卫生组织发布了首个关于将胰高血糖素样肽-1类药物用于治疗肥胖的全球指南。2025年9月，世卫组织已将GLP-1类药物纳入《基本药物目录》，用于高风险人群的2型糖尿病管理。此次新指南对GLP-1药物用于肥胖治疗提出了有条件的推荐，强调应将其作为包括健康饮食、规律运动和专业医务工作者健康指导在内的综合管理方案的一部分。新指南有助于降低因肥胖及其并发症带来的医疗成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200204a723bda3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200204a723bda3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4144","BK4590","IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","GLP","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","BK4588","LU1093756168.USD","BK4599"],"gpt_icon":1},{"id":"2588268940","title":"诺和诺德准备12月份在印度市场推出Ozempic","url":"https://stock-news.laohu8.com/highlight/detail?id=2588268940","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588268940?lang=zh_cn&edition=full","pubTime":"2025-12-04 02:26","pubTimestamp":1764786401,"startTime":"0","endTime":"0","summary":"诺和诺德准备12月份在印度市场推出Ozempic。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204023905978e50bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204023905978e50bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BZ1G4Q59.USD","BK4007","BK4599","BK4588","BK4585","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD"],"gpt_icon":0},{"id":"2588093940","title":"“多事之秋”中，诺和诺德迎来三项积极进展…","url":"https://stock-news.laohu8.com/highlight/detail?id=2588093940","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588093940?lang=zh_cn&edition=full","pubTime":"2025-12-03 07:31","pubTimestamp":1764718297,"startTime":"0","endTime":"0","summary":"相比之下，皮下和口服的安慰剂组，其HbA1c仅下降0.2%和0.4%。为高剂量Wegovy获批按下“加速键”面对礼来登顶全球首家万亿美元市值药企的强势崛起，诺和诺德正按下“加速键”。此举被广泛视为诺和诺德应对礼来替尔泊肽市场占有率快速提升的积极策略。帕西生长激素新适应症在华申报获受理2025年11月27日，诺和诺德在中国也迎来新的监管进展。随着帕西生长激素等国际创新药加速进入中国，这一高价值赛道或将迎来激烈","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203093549a72046bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203093549a72046bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BZ1G4Q59.USD","BK4007","BK4599","BK4588","BK4585","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2588408504","title":"阿尔茨海默病研发不易，诺和诺德、强生新药试验接连失败！","url":"https://stock-news.laohu8.com/highlight/detail?id=2588408504","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588408504?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:20","pubTimestamp":1764645651,"startTime":"0","endTime":"0","summary":"近期，阿尔茨海默病疗法的开发就接连遭遇滑铁卢。在同一时期，强生的阿尔茨海默病项目之一也宣布失败。虽然近期多家药企在阿尔茨海默病药物研发方面遭遇滑铁卢，但在众多药企涌入该赛道持续推动创新的背景下，还是有不少药企迎来了好消息。如万邦德、绿叶制药等多家国内药企就相继公布了阿尔茨海默病研究新进展。LY03017拟用于治疗阿尔茨海默病精神病性障碍、帕金森病精神病性障碍、精神分裂症阴性症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202112442978aec9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JNJ","LU1032955483.USD","LU0234570918.USD","LU0203347892.USD","LU0154236417.USD","IE00BGHQF631.EUR","LU1221951129.SGD","LU1061106388.HKD","BK4007","IE00BLSP4239.USD","LU0122379950.USD","LU0432979614.USD","LU2129689431.USD","IE0034235303.USD","LU1066051225.USD","LU1057294990.SGD","LU1267930813.SGD","LU1059921491.USD","LU1718418525.SGD","BK4504","LU2089984988.USD","LU2750360641.GBP","LU0345769631.USD","LU1066051498.USD","BK4585","LU1032466523.USD","LU0882574055.USD","IE00B19Z3B42.SGD","LU1162221912.USD","BK4588","NVO","LU1732799900.SGD","LU1496350502.SGD","LU0114720955.EUR","IE0009355771.USD","BK4581","LU0795875086.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2133065610.SGD","BK4592","LU2430703095.HKD","IE00BVYPNV92.GBP","LU2471134523.USD","IE00BFXG1179.USD","BK4568","LU2471134879.HKD","IE00BN8TJ469.HKD","BK4534","LU2112291526.USD"],"gpt_icon":1},{"id":"2588603321","title":"美国OTC市场Novo Nordisk A/S盘中异动 股价大涨4.40%报48.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588603321","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588603321?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:06","pubTimestamp":1764601583,"startTime":"0","endTime":"0","summary":"北京时间2025年12月01日23时06分，美国OTC市场Novo Nordisk A/S股票出现波动，股价大幅拉升4.40%。截至发稿，该股报48.81美元/股，成交量1775股，换手率0.00%，振幅3.68%。美国OTC市场Novo Nordisk A/S股票所在的制药行业中，整体跌幅为0.57%。美国OTC市场Novo Nordisk A/S公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512012306239789f34f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512012306239789f34f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVO","IE00BKVL7J92.USD","LU1093756168.USD","BK4532","BK4585","LU1093756325.SGD","IE00BZ1G4Q59.USD","NONOF","LU0154236417.USD","BK4588","BK4007"],"gpt_icon":1},{"id":"2588153725","title":"诺和诺德：泡沫挤出后，未来仍值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2588153725","media":"北海茶客投研笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588153725?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:48","pubTimestamp":1764575290,"startTime":"0","endTime":"0","summary":"随后，礼来启动瑞他鲁肽头对头替尔泊肽在减重上的3期临床，远期应该是希望成为迭代产品。超重且伴有2型糖尿病适应症上，受试者68周平均减重15.7%，安慰剂组减重3.1%。替尔泊肽同适应症平均减重15%，再度与替尔泊肽相当。Cagrisema预计将在2026Q1向FDA申报上市，预计上市时替尔泊肽已逐步完成峰值爬坡。减重上，替尔泊肽以20.2% VS 13.7%取胜，且严重不良事件发生率替尔4.8%、司美3.5%，因不良反应停药率替尔3.0% VS司美4.8%。接近礼来替尔泊肽，2025Q4将向FDA申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201174213a4c57c66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201174213a4c57c66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU1093756325.SGD","NVO","BK4585","BK4007","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","IE00BKVL7J92.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2588090743","title":"诺和诺德年内股价下跌43.10%！礼来替尔泊肽证明自己是真正的“减肥药之王”","url":"https://stock-news.laohu8.com/highlight/detail?id=2588090743","media":"GLP1减重宝典","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588090743?lang=zh_cn&edition=full","pubTime":"2025-12-01 12:19","pubTimestamp":1764562796,"startTime":"0","endTime":"0","summary":"在此背景下，诺和诺德股价近期出现明显回落，而礼来则迎来新一轮估值上升。截至2025年9月，礼来在美国GLP-1药物处方份额达到58%，诺和诺德为42%。替尔泊肽因显著优于司美格鲁肽的减重幅度与代谢改善效果，被视为“下一代减肥药”的代表。在替尔泊肽的带动下，礼来股价一路上涨，市值突破1万亿美元，成为全球首批迈入该规模的医疗公司。资本市场普遍认为，礼来已成为GLP-1与肥胖代谢药物领域的新霸主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201125219a4c4e522&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201125219a4c4e522&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0820561818.USD","LLY","LU0889565916.HKD","LU2552382132.HKD","LU0432979614.USD","LU2471134879.HKD","LU1069344957.HKD","LU0353189763.USD","LU0234572021.USD","SG9999001176.USD","LU0823434740.USD","LU2750360997.AUD","LU2471134796.USD","LU2552382215.SGD","LU1232071149.USD","LU2471134523.USD","BK4599","LU2750360641.GBP","LU0061475181.USD","LU1814569148.SGD","LU2456880835.USD","LU0109394709.USD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","LU0943347566.SGD","LU0096364046.USD","LU0823434583.USD","LU1868837300.USD","SGXZ57979304.SGD","LU0094547139.USD","LU2552382058.USD","LU2471134952.CNY","LU0316494557.USD","LU0708995401.HKD","LU0006306889.USD","LU2236285917.USD","LU0154236417.USD","LU0320765059.SGD","IE00BJLML261.HKD","SG9999015945.SGD","LU2112291526.USD","LU0354030438.USD","NVO","LU1057294990.SGD","LU2237443465.HKD","SGXZ81514606.USD","LU1551013342.USD","IE00BWXC8680.SGD","LU0882574055.USD","LU0354030511.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0479},{"period":"1month","weight":0.0232},{"period":"3month","weight":-0.0835},{"period":"6month","weight":-0.37},{"period":"1year","weight":-0.5497},{"period":"ytd","weight":-0.4154}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.1345},{"period":"ytd","weight":0.1759}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.522727,"avgChangeRate":0.119015},{"month":2,"riseRate":0.613636,"avgChangeRate":0.028062},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048491}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}